GlassScriptPhysician profile
Warren R Amos
NPI 1275537755
$4,094.13
in general payments reported to CMS, 2019-2025
39 companies · $780 in 2025
The $780 reported for 2025 was more than what 81% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,298 · 2020: $219 · 2021: $294 · 2022: $478 · 2023: $426 · 2024: $598 · 2025: $780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,805.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,804.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Brainlab, INC. | $870.68 | 2019 | |
| Amgen INC. | $359.34 | 2019-2022 | |
| Janssen Biotech, INC. | $312.23 | 2019-2025 | Erleada, Balversa, Akeega |
| Pfizer INC. | $254.77 | 2019-2023 | |
| Eisai INC. | $230.67 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $206.54 | 2020-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $163.31 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $155.38 | 2022-2025 | Libtayo |
| Genentech USA, INC. | $129.11 | 2024-2025 | Polivy, Tecentriq, Lunsumio |
| Lilly USA, LLC | $123.19 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Janssen Scientific Affairs, LLC | $122.26 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $117.80 | 2023-2025 | Opdivo |
| Beigene USA, INC. | $91.66 | 2022-2024 | Brukinsa |
| Ipsen Biopharmaceuticals, INC | $91.02 | 2020-2025 | Onivyde |
| Sumitomo Pharma America, INC. | $80.92 | 2023-2025 | Orgovyx |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Warren Amos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.